Value-based estimate of market size and opportunity for economic benefit through innovative pancreatic cancer (PC) therapies.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16790-e16790
Author(s):  
Vincent J. Picozzi ◽  
Victoria G. Manax ◽  
Semmie Kim ◽  
Zachary Wintrob ◽  
Margaret T. Mandelson ◽  
...  
Keyword(s):  
Economic Benefit ◽  
Economic Value ◽  
Cost Of Care ◽  
List Price ◽  
Total Cost ◽  
Average Value ◽  
Incidence Data ◽  
Treatment Prevalence ◽  
Life Years ◽  
Commercial Opportunity

e16790 Background: Over the past 20 years, cancer drugs have contributed to increased life expectancy, reduced mortality, decreased hospitalization and decreased use of medical services. The economic value of these improvements is about as large as the value of the increase in the US gross domestic product during that time period. Recently, a health economic study presented at ASCO GI 2020 cited that every $1 (adjusted for inflation) spent on innovative PC treatments reduced non-drug expenditures by $9, thereby lowering the total cost of care for PC patients. Accordingly, the commercial opportunity of a new therapy should be measured by some combination of the clinical, economic and social value generated. We demonstrate the value of a novel PC drug from this perspective. Methods: Analysis of SEER survival and incidence data between 2008 and 2016 shows the introduction of new medicines for PC of all stages was associated with a cumulative increase of 26,456 life years, or 2.52 life years per patient. It was also associated with quality of life improvements, measured by a decline in hospitalizations rates and emergency room visits that can also lead to more days at work, at school and with family. Several studies have suggested the average value of an additional year of life, for the age of a typical patient diagnosed with PC, is at least $250,000. Using this figure, the value of 26,456 life years gained from 2008-2016 is $6.61 billion (26,456*$250,000) to patients, the healthcare system and society, as a result of advancing medical innovation for patients with PC. Results: The median annual list price of a life-enhancing cancer therapy is $150,000 per patient. Using the NCI treatment prevalence estimator (holding incidence constant), we estimate that between 2020-2025, there will be an additional 10,728 advanced PC patients requiring treatment who could benefit from innovative drugs. The total cost of these drugs for these patients would be $1.61 billion. However, the economic value of the life years saved would be $6.76 billion (10,728*2.52 life years*$250,000 = $6.76 billion). A review of cancer medicine payor coverage suggests a new PC therapy that produces such value would be able to obtain coverage from US payors given this value-based price. Conclusions: A value-based approach to estimating the opportunity for clinical and economic benefit reveals significant potential for new PC medicines.

scholarly journals The Economic Impact of Compassionate Use of Medicines

2021 ◽  
Author(s):  
Claudio Jommi ◽  
Federico Pantellini ◽  
Lisa Stagi ◽  
Maria Verykiou ◽  
Marianna Cavazza
Keyword(s):  
Adverse Events ◽  
Economic Impact ◽  
Economic Benefit ◽  
Muscular Atrophy ◽  
Economic Value ◽  
Diagnostic Procedures ◽  
Compassionate Use ◽  
Cancer Treatments ◽  
Total Cost ◽  
Mean Cost

Abstract BACKGROUND: Compassionate use programs (CUP) for medicines respond to the ethical imperative of providing earlier access to medicines to patients not recruited in trials. While the economic impact of clinical trials has been already investigated, no evidence on the net economic benefit of CUP exists. This research aims to fill the information gap by estimating the economic consequences of 11 CUP in Italy conducted between May 2015 and December 2020 from the perspective of health care payers. Eight programs concern cancer treatments, two refer to drugs for spinal muscular atrophy, and one is indicated for multiple sclerosis.METHODS: The net economic benefit includes the avoided costs from the Standard of Care (SoC) the patients would have received if they had not joined the CUP, and costs not covered by the pharmaceutical industry but instead sustained by payers, such as those associated to adverse events (only severe sides effects resulting in hospitalisation and attributed to CUP medicines), and costs for combination therapies and diagnostic procedures not used with the SoC. The SoC costing relied on publicly available data. Information on adverse events and diagnostic procedures was retrieved from the CUP and monetized using the relevant fee for episode or service. One CUP was excluded since a SoC was not identified.RESULTS: 2,712 patients were treated in the 11 CUP, where SoC was identified. The SoC mean cost per patient ranges from €11,415 to €20,299. The total cost of the SoC ranged between €31.0 and €55.1 million. The mean cost per patient covered by hospitals hosting CUP was equal to €1,646, with a total cost of €4.5 million. The net economic benefit ranged from €26.5 million to €50.6 million (€17.8 million - €42.0 million for cancer treatments). CONCLUSIONS: Despite research limitations, this paper illustrates for the first time the net economic impact of CUP in oncology patients from a payer perspective. It is important to integrate these estimates with the prospective effects of CUP implementation, i.e., the economic value of the comparative benefit profile of medicines used in CUP versus the SoC, including effects from a societal perspective.

Economic Value of Pavement for the Elderly: Case Study of Bangkok, Thailand

2018 ◽  
Vol 9 (11) ◽  
pp. 927-937
Author(s):  
Somskaow Bejranonda ◽  
◽  
Aekkapat Laksanacom ◽  
Waranan Tantiwat ◽  
◽  
...  
Keyword(s):  
Contingent Valuation Method ◽  
Economic Value ◽  
The Elderly ◽  
Pavement Management ◽  
Sustainable Urban Development ◽  
Public Facility ◽  
Average Value ◽  
Valuation Method ◽  
The People ◽  
The City

Based on the concept of a livable and global age-friendly city, pavements are a public facility that the city should provide to the people. Appropriate pavements will be beneficial for the people, particularly for good quality of life for the elderly to move around in the city. This study explored the behaviour of the elderly in the use of pavements and the problems confronted. The study also evaluated the value of the pavement walking area as it reflected the benefits of pavements to the elderly by applying the Contingent Valuation Method (CVM). During March-May 2017, data were collected using interviews with 601 elderly living in Bangkok. The study indicated that the main problem for senior citizens regarding their use of pavements was from being disturbed by motorbikes riding on the pavements. The average value of pavement for the elderly was about THB 160 (USD 5.30) per person per year. Thus, the benefits of pavements to the elderly in Bangkok was approximately THB 158 million (USD 5.2 million) per year. Thus, policy makers should make proper budget allocations for elderly-friendly pavement management and seriously address the problems confronting the elderly in using pavements, to maximize the usefulness of pavements not only for the elderly but also for the public and to support a sustainable urban development.

scholarly journals Economic value of protected areas via visitor mental health

2019 ◽  
Vol 10 (1) ◽  
Author(s):  
Ralf Buckley ◽  
Paula Brough ◽  
Leah Hague ◽  
Alienor Chauvenet ◽  
Chris Fleming ◽  
...  
Keyword(s):  
Mental Health ◽  
Protected Areas ◽  
Protected Area ◽  
Economic Value ◽  
Future Research ◽  
Global Estimate ◽  
Conservation Policies ◽  
Life Years ◽  
Order Of Magnitude ◽  
Individual Scale

Abstract We evaluate methods to calculate the economic value of protected areas derived from the improved mental health of visitors. A conservative global estimate using quality-adjusted life years, a standard measure in health economics, is US$6 trillion p.a. This is an order of magnitude greater than the global value of protected area tourism, and two to three orders greater than global aggregate protected area management agency budgets. Future research should: refine this estimate using more precise methods; consider interactions between health and conservation policies and budgets at national scales; and examine links between personalities and protected area experiences at individual scale.

PMU41 Clinical Pharmacy Provider Dashboards May Prevent Avoidable Adverse Events and Reduce Total Cost of Care

2021 ◽  
Vol 24 ◽  
pp. S151-S152
Author(s):  
E. Lucas ◽  
Snow LM Tyndall ◽  
B. Mohundro ◽  
W.E. Seggerman ◽  
M. Carby ◽  
...  
Keyword(s):  
Adverse Events ◽  
Clinical Pharmacy ◽  
Cost Of Care ◽  
Total Cost

Dispersion in total cost of care for Medicare fee-for-service (FFS) patients with metastatic pancreatic cancer receiving FDA-approved/NCCN Category 1 regimens at 340B verus non-340B institutions.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18843-e18843
Author(s):  
Helen Latimer ◽  
Samantha Tomicki ◽  
Gabriela Dieguez ◽  
Paul Cockrum ◽  
George P. Kim
Keyword(s):  
Pancreatic Cancer ◽  
Cost Of Care ◽  
Metastatic Pancreatic Cancer ◽  
Fee For Service ◽  
Total Cost ◽  
Diagnosis Codes ◽  
Heavily Pretreated ◽  
Icd 10 ◽  
Liposomal Irinotecan ◽  
Line Of Therapy

e18843 Background: The Department of Health and Human Services (HHS) designed the 340B drug pricing program to allow institutions that service specialty populations to acquire drugs at lower prices. Objective: To analyze the dispersion in total cost of care (TCOC) for Medicare FFS patients (pts) with metastatic pancreatic cancer (m-PANC) treated at 340B or non-340B institutions, by NCCN Category 1 regimen. Methods: We identified pts with m-PANC using ICD-10 diagnosis codes in the 2016-18 Medicare Parts A/B/D 100% Research Identifiable Files. Study pts had 2+ claims with a pancreatic cancer diagnosis and Medicare FFS coverage for 6 months pre- and 3 months post-metastasis diagnosis. Study pts were treated with NCCN Category 1 regimens: 1L gemcitabine monotherapy (gem-mono), 1L gemcitabine/nab-paclitaxel (gem-nab), 1L FOLFIRINOX (FFX), and 2L liposomal irinotecan-based regimen (nal-IRI). Pts were attributed to 340B or non-340B institutions based on plurality of chemotherapy claims. TCOC reflects insurer-paid services per line of therapy (LOT) for 3 categories: chemotherapy/supportive drugs (chemo/Rx), inpatient care (IP), and other outpatient care (OP). We grouped pts by quartile (qrt) and evaluated drivers of TCOC and mean rates of admissions (admits/pt). Results: We identified 2,697 (340B) and 3,839 (non-340B) pts taking NCCN Category 1 regimens. Gem-mono represented 1% and 4% of all pts in 340B and non-340B institutions, respectively. Gem-nab accounted for 72% of pts in both cohorts. For gem-nab, FFX, and nal-IRI pts, median TCOC was similar in both cohorts, although mean TCOC by qrt was lower at 340B institutions than non-340B institutions, except for gem-nab in the 1st qrt. The components of TCOC were similar between 340B and non-340B institutions in all qrts. In both cohorts, % IP costs increased between the 1st and 4th qrt (340B:15% to 23%, non-340B:14% to 25%). From the 1st to the 4th qrt, admits/pt increased in both cohorts. In the 340B cohort, nal-IRI pts had the lowest admits/pt while gem-nab pts had the highest in all qrts. In the non-340B cohort, nal-IRI pts had the lowest admits/pt except for in the 1st qrt. Conclusions: Median TCOC was lower at 340B institutions than non-340B institutions for all regimens, and the range of TCOC dispersion was also smaller at 340B institutions. Across qrts, chemotherapy accounted for approximately half the TCOC; however, IP costs were proportionally higher in the 4th qrt. Comparing regimens, despite 2L nal-IRI pts being more heavily pretreated, median costs in each cohort were similar to 1L gem-nab and 1L FFX, while admits/pt were generally lower than 1L gem-nab and 1L FFX across qrts and cohorts.

Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System

2020 ◽  
Author(s):  
Julia Gonzalez ◽  
Diana Carolina Andrade ◽  
JianLi Niu
Keyword(s):  
Healthcare System ◽  
Treatment Success ◽  
Standard Of Care ◽  
Cost Of Care ◽  
Secondary Outcome ◽  
Total Cost ◽  
Skin Structure ◽  
Cost Consequence ◽  
The Difference ◽  
The Cost

Abstract Background Acute bacterial skin and skin structure infections (ABSSSIs) are common infectious diseases that cause a significant economic burden on the healthcare system. This study aimed to compare the cost-effectiveness of dalbavancin vs standard of care (SoC) in the treatment of ABSSSI in a community-based healthcare system. Methods This was a retrospective study of adult patients with ABSSSI treated with dalbavancin or SoC during a 27-month period. Patients were matched based on age and body mass index. The primary outcome was average net cost of care to the healthcare system per patient, calculated as the difference between reimbursement payments and the total cost to provide care to the patient. The secondary outcome was proportion of cases successfully treated, defined as no ABSSSI-related readmission within 30 days after the initiation of treatment. Results Of the 418 matched patients, 209 received SoC and 209 received dalbavancin. The average total cost of care per patient was greater with dalbavancin vs SoC ($4770 vs $2709, P < .0001). The average reimbursement per patient was $3084 with dalbavancin vs $2633 SoC (P = .527). The net cost, calculated as revenue minus total cost, was $1685 with dalbavancin vs $75 with SoC (P = .013). The overall treatment success rate was 74% with dalbavancin vs 85% with SoC (P = .004). Conclusions Dalbavancin was more costly than SoC for the treatment of ABSSSI, with a higher 30-day readmission rate. Dalbavancin does not offer an economic or efficacy advantage.

scholarly journals Economic Impacts on Human Health Resulting from the Use of Mercury in the Illegal Gold Mining in the Brazilian Amazon: A Methodological Assessment

2021 ◽  
Vol 18 (22) ◽  
pp. 11869
Author(s):  
Leonardo Barcellos de Bakker ◽  
Pedro Gasparinetti ◽  
Júlia Mello de Queiroz ◽  
Ana Claudia Santiago de Vasconcellos
Keyword(s):  
Human Health ◽  
Gold Mining ◽  
Economic Value ◽  
Brazilian Amazon ◽  
Economic Losses ◽  
Small Scale ◽  
Environmental Damage ◽  
Statistical Life ◽  
Life Years ◽  
Methodological Assessment

Artisanal small-scale gold mining (ASGM) in the Amazon results in the dumping of tons of mercury into the environment annually. Despite consensus on the impacts of mercury on human health, there are still unknowns regarding: (i) the extent to which mercury from ASGM can be dispersed in the environment until it becomes toxic to humans; and (ii) the economic value of losses caused by contamination becomes evident. The main objective of this study is to propose a methodology to evaluate the impacts of ASGM on human health in different contexts in the Brazilian Amazon. We connect several points in the literature based on hypotheses regarding mercury dispersion in water, its transformation into methylmercury, and absorption by fish and humans. This methodology can be used as a tool to estimate the extent of environmental damage caused by artisanal gold mining, the severity of damage to the health of individuals contaminated by mercury and, consequently, can contribute to the application of fines to environmental violators. The consequences of contamination are evaluated by dose-response functions relating to mercury concentrations in hair and the development of the following health outcomes: (i) mild mental retardation, (ii) acute myocardial infarction, and (iii) hypertension. From disability-adjusted life years and statistical life value, we found that the economic losses range from 100,000 to 400,000 USD per kilogram of gold extracted. A case study of the Yanomami indigenous land shows that the impacts of mercury from illegal gold mining in 2020 totaled 69 million USD, which could be used by local authorities to compensate the Yanomami people.

scholarly journals Quantitative Ethobotany of Gnetum africanum Welw. (Gnetaceae) in Massoumboum, Littoral Region of Cameroon

2019 ◽  
Vol 8 (2) ◽  
pp. 19
Author(s):  
Jean Lagarde Betti ◽  
Pascal Eric Billong Fils ◽  
Prisca Toffon ◽  
Eric Wété ◽  
Jules Romain Ngueguim ◽  
...  
Keyword(s):  
Economic Value ◽  
Sampling Rate ◽  
Quantitative Ethnobotany ◽  
Distribution Area ◽  
Ethnobotanical Survey ◽  
Average Value ◽  
Forest Inventories ◽  
Littoral Region ◽  
The City ◽  
Cfa Franc

Gnetum africanum Welw. is a plant specie of Central and West Africa, a Non Timber Forest Product (NTFP) with high nutritional, medicinal and economic value. In Cameroon, its leaves are recognized by the forestry administration as a special product. Strong demand combined with destructive harvesting techniques has resulted in its rarity in its distribution area. The objective of this work is to characterize the harvesting and trade of G. africanaum, and to assess its abundance (density and structure) in order to appreciate the economic value of the Lehman agroforest system (ALM) based in Massoumboum, a village located at 30 Km of Douala town, the economical capital of Cameroon. An ethnobotanical survey was conducted among harvesters and sellers of G. africanum in the ALM and in adjacent markets. An inventory of G. africanum stems and leaves was carried out at an overall sampling rate of 9.52%. The study revealed that, harvesting of G. africanum is freely done by women, youngers and elders. They start their activity early in the morning and convey their products to markets located in the periphery and inside the city of Douala. The price of the gramme is too high in the periphery than in the city, averaging 0.58 CFA franc. This price is high in the dry season due to the scarcity of other agricultural vegetables. The inventories conducted revealed densities of 6 191 stems/ha and 119 548 leaves/ha, with the high density of leaves obtained in less perturbed plots. The combination of field data (forest inventories) with those obtained in the markets (trade data), what we call « quantitative ethnobotany », allowed us to appreciate the temporal economic value (EV) of the ALM. This EV ranges from 500 000 - 700 000 CFA franc, for an average value of 37 059.9 CFA franc /ha. If well managed, G. africanum can contribute not only to the economy of the women-harvesters, but also to the economy of the ALM. The glaring development challenge of the background of what precedes is the development of non-detriment findings (NDF) for G. africanum in Cameroon. These consist of setting tools which aims to sustain the resource and trade such as the delimitation of Gnetum Allocation Units (GAU), as well as the development and implementation of simple management plans (SMPs).

Sign in / Sign up

Export Citation Format

Share Document